The data displays the leading antacid tablet vendors in the U.S. in 2016, based on sales. In that year, Boehringer Ingelheim Pharm generated sales of 151.6 million USD. Total sales of U.S. antacid tablet vendors amounted to about 2.21 billion USD in 2016.
Private label | 858.2 |
Pfizer | 312.3 |
Procter & Gamble | 256.9 |
Glaxosmithkline | 197.3 |
Boehringer Ingelheim Pharm | 151.6 |
Novartis Consumer Health |
136.9 |
Johnson & Johnson-Merck Consumer Pharmaceuticals |
96.7 |
McNeil Nutritionals | 38.9 |
Bayer Healthcare | 36.8 |
Medtech Products | 27.6 |